- About Yifang
Yifang (Francis) Huang, M.S., M.A. joined drug discovery group of the Lieber Institute in August, 2011 as a medicinal chemist. His main focus is designing and synthesizing bioactive compounds targeting neurodevelopmental disorders such as schizophrenia. Prior to joining the Institute, he worked at SAIC, Frederick in supporting NCI on cancer related drug discovery during 2010 and 2011. Previously, he worked in drug discovery at Johnson & Johnson Pharmaceutical Research and Development for eleven years where he made significant contributions to Alzheimer’s disease, epilepsy, and inflammation programs.